Konvalis (Convalis) | KtoiKak.com
Home Architecture DIETOLOGY diet root vegetables dairy products meat products and vegetables juices supplements the product composition berry fruits cinema and music, movie actors actors biography biography of musicians glucosamine and actors from the movie Quotes LITERATURE protagonists summary of who the author is a synonym to the word MEDICINE amino acids anatomy and physiology of the disease A C D & M F I C vitamins germs / bacteria minerals medication glucosamine / drugs A B C D E F G H I J K L M N O P Q R S T U V W X Y Z FAMILY, glucosamine CHILDREN, HOUSE children Explanatory Beauty Tips Dictionary glucosamine of Humor
Capsule size, yellow contents glucosamine of capsules - amorphous or crystalline powder, white or white with a slightly yellowish tint. 1 caps. Gabapentin 300 mg. Inactive ingredients: lactose monohydrate, pregelatinized corn starch, glucosamine talc, magnesium stearate. Ingredients glucosamine Gelatin Capsules: titanium dioxide, gelatin, iron oxide yellow.
The anticonvulsant drug. Gabapentin is structurally similar to c neurotransmitter gamma-aminobutyric glucosamine acid (GABA), but its mechanism glucosamine of action differs from that of certain other drugs that interact with GABA-receptors, glucosamine including valproate, barbiturates, glucosamine benzodiazepines, GABA-transaminase inhibitors, inhibitors capture glucosamine GABA, GABA agonists, and prodrugs of GABA. He does not have the properties of GABA-ergic and does not affect the metabolism of the capture and GABA.
Preliminary studies have shown that gabapentin is associated with α2-δ-subunit of voltage-dependent calcium channels and inhibits the flow of calcium ions, which plays an important role in the occurrence glucosamine of neuropathic pain. Other mechanisms of action of gabapentin for neuropathic pain are: reduction of glutamate-dependent neuronal cell death, increased synthesis of GABA, inhibition of monoamine neurotransmitter release.
Gabapentin at clinically relevant concentrations, does not bind to receptors or other drugs commonly neurotransmitter receptors including GABAA, GABAB, benzodiazepine, glutamate, glycine, or N-methyl-D-aspartate (NMDA). Unlike phenytoin, carbamazepine glucosamine and gabapentin does not interact with sodium channels in vitro. Gabapentin partially attenuate the effects of glutamate NMDA receptor glucosamine agonists in some tests in vitro, but only at concentrations greater than 100 micromoles, which is not achieved in vivo. Gabapentin slightly reduces the release of monoamine neurotransmitters in vitro.
After oral administration of gabapentin Cmax in plasma is reached after 2-3 hours bioavailability of gabapentin is not proportional to the dose, as increasing the dose when it is reduced. Absolute bioavailability when receiving gabapentin capsules is approximately 60%. Simultaneous food intake, including with high content of fat, has no effect on pharmacokinetics.
Pharmacokinetics do not vary with repeated use; Css in plasma can be predicted on the basis of a single dose of the drug. Gabapentin is almost bound to plasma proteins (<3%), Vd is about 57.7 liters.
The concentrations glucosamine of gabapentin in plasma children glucosamine aged 4 to 12 are generally similar to those of adults. Clearance from plasma glucosamine gabapentin reduced in the elderly and in patients with impaired renal function. Elimination rate constant, plasma glucosamine clearance and renal clearance are directly proportional to KK. Gabapentin glucosamine is removed from plasma by hemodialysis.
When partial seizures as monotherapy or used as an aid in adults and children over 12 years of age, treatment is initiated with a dose of 300 mg 1 time / day and gradually increase it to 900 mg / day: day 1 - 300 mg 1 time / day, in Day 2 - 300 mg 2 times / day for 3 days - 300 mg 3 times / day. Subsequently possible to further increase the dose. The dose is Konvalisa 900-1200 mg / day. The maximum dose - 3.6 g / day in 3 divided doses equal doses with an interval of 8 hours
Neuropathic pain medication prescribed for adults in a daily dose of 1 300 mg 1 time / day, in two day - 300 mg 2 times / day for 3 days - 300 mg 3 times / day. With intense pain Konvalis be administered from day 1, 300 mg 3 times / day. Depending on the effectiveness glucosamine of the dose can be gradually increased, but not more than 3.6 g / day.
For patients with impaired renal function, the daily dose is: with CC 50-79 ml / min - 600-1800 mg / day, 30-49 ml / min - 300-900 mg / day, 15-29 ml / min - 300 - 600 mg / day, less than 15 ml / min - 300 mg on alternate days or daily.
Dermatological reactions: skin rash. Other: asthenic syndrome, flu syndrome, glucosamine headache, infections, pain, various locations, peripheral edema, weight gain.
CNS and peripheral nervous system: dizziness, glucosamine hyperkinesia, strengthening, weakening or absence of tendon reflexes, paresthesia, anxiety, hostility, amnesia, ataxia, confusion, impaired coordination, depression
Home Architecture DIETOLOGY diet root vegetables dairy products meat products and vegetables juices supplements the product composition berry fruits cinema and music, movie actors actors biography biography of musicians glucosamine and actors from the movie Quotes LITERATURE protagonists summary of who the author is a synonym to the word MEDICINE amino acids anatomy and physiology of the disease A C D & M F I C vitamins germs / bacteria minerals medication glucosamine / drugs A B C D E F G H I J K L M N O P Q R S T U V W X Y Z FAMILY, glucosamine CHILDREN, HOUSE children Explanatory Beauty Tips Dictionary glucosamine of Humor
Capsule size, yellow contents glucosamine of capsules - amorphous or crystalline powder, white or white with a slightly yellowish tint. 1 caps. Gabapentin 300 mg. Inactive ingredients: lactose monohydrate, pregelatinized corn starch, glucosamine talc, magnesium stearate. Ingredients glucosamine Gelatin Capsules: titanium dioxide, gelatin, iron oxide yellow.
The anticonvulsant drug. Gabapentin is structurally similar to c neurotransmitter gamma-aminobutyric glucosamine acid (GABA), but its mechanism glucosamine of action differs from that of certain other drugs that interact with GABA-receptors, glucosamine including valproate, barbiturates, glucosamine benzodiazepines, GABA-transaminase inhibitors, inhibitors capture glucosamine GABA, GABA agonists, and prodrugs of GABA. He does not have the properties of GABA-ergic and does not affect the metabolism of the capture and GABA.
Preliminary studies have shown that gabapentin is associated with α2-δ-subunit of voltage-dependent calcium channels and inhibits the flow of calcium ions, which plays an important role in the occurrence glucosamine of neuropathic pain. Other mechanisms of action of gabapentin for neuropathic pain are: reduction of glutamate-dependent neuronal cell death, increased synthesis of GABA, inhibition of monoamine neurotransmitter release.
Gabapentin at clinically relevant concentrations, does not bind to receptors or other drugs commonly neurotransmitter receptors including GABAA, GABAB, benzodiazepine, glutamate, glycine, or N-methyl-D-aspartate (NMDA). Unlike phenytoin, carbamazepine glucosamine and gabapentin does not interact with sodium channels in vitro. Gabapentin partially attenuate the effects of glutamate NMDA receptor glucosamine agonists in some tests in vitro, but only at concentrations greater than 100 micromoles, which is not achieved in vivo. Gabapentin slightly reduces the release of monoamine neurotransmitters in vitro.
After oral administration of gabapentin Cmax in plasma is reached after 2-3 hours bioavailability of gabapentin is not proportional to the dose, as increasing the dose when it is reduced. Absolute bioavailability when receiving gabapentin capsules is approximately 60%. Simultaneous food intake, including with high content of fat, has no effect on pharmacokinetics.
Pharmacokinetics do not vary with repeated use; Css in plasma can be predicted on the basis of a single dose of the drug. Gabapentin is almost bound to plasma proteins (<3%), Vd is about 57.7 liters.
The concentrations glucosamine of gabapentin in plasma children glucosamine aged 4 to 12 are generally similar to those of adults. Clearance from plasma glucosamine gabapentin reduced in the elderly and in patients with impaired renal function. Elimination rate constant, plasma glucosamine clearance and renal clearance are directly proportional to KK. Gabapentin glucosamine is removed from plasma by hemodialysis.
When partial seizures as monotherapy or used as an aid in adults and children over 12 years of age, treatment is initiated with a dose of 300 mg 1 time / day and gradually increase it to 900 mg / day: day 1 - 300 mg 1 time / day, in Day 2 - 300 mg 2 times / day for 3 days - 300 mg 3 times / day. Subsequently possible to further increase the dose. The dose is Konvalisa 900-1200 mg / day. The maximum dose - 3.6 g / day in 3 divided doses equal doses with an interval of 8 hours
Neuropathic pain medication prescribed for adults in a daily dose of 1 300 mg 1 time / day, in two day - 300 mg 2 times / day for 3 days - 300 mg 3 times / day. With intense pain Konvalis be administered from day 1, 300 mg 3 times / day. Depending on the effectiveness glucosamine of the dose can be gradually increased, but not more than 3.6 g / day.
For patients with impaired renal function, the daily dose is: with CC 50-79 ml / min - 600-1800 mg / day, 30-49 ml / min - 300-900 mg / day, 15-29 ml / min - 300 - 600 mg / day, less than 15 ml / min - 300 mg on alternate days or daily.
Dermatological reactions: skin rash. Other: asthenic syndrome, flu syndrome, glucosamine headache, infections, pain, various locations, peripheral edema, weight gain.
CNS and peripheral nervous system: dizziness, glucosamine hyperkinesia, strengthening, weakening or absence of tendon reflexes, paresthesia, anxiety, hostility, amnesia, ataxia, confusion, impaired coordination, depression
No comments:
Post a Comment